PROGNOSTIC FACTORS IN PATIENTS WITH RELAPSED OR REFRACTORY SYSTEMIC ANAPLASTIC LARGE T‐CELL LYMPHOMA (ALCL) RECEIVING BRENTUXIMAB VEDOTIN AND OUTCOME AFTER TREATMENT FAILURE.
Sign Up to like & getrecommendations! Published in 2017 at "Hematological Oncology"
DOI: 10.1002/hon.2438_112
Abstract: Introduction: Despite high overall 5‐year survival rates for childhood HL and sALCL, improved options are needed for patients (pts) who do not respond to, or relapse following, initial therapy. This phase 1/ 2 open‐label, dose‐escalation… read more here.
Keywords: salcl pts; pts treated; treatment; brentuximab vedotin ... See more keywords
395 Outcomes of carbotaxol in carcinosarcoma: a retrospective study at the brazilian national cancer institute (INCA)
Sign Up to like & getrecommendations! Published in 2019 at "International Journal of Gynecological Cancer"
DOI: 10.1136/ijgc-2019-igcs.395
Abstract: Objectives Endometrial carcinosarcomas (EC) are rare metaplastic tumors with dual composition of mesenchymal and epithelial elements, seen as a good example of epithelial-mesenchymal transition (EMT). The current study evaluated the efficacy and safety of Carbotaxol… read more here.
Keywords: pts treated; 395 outcomes; outcomes carbotaxol; cancer ... See more keywords
Pharmacodynamics (PD) and genomic profiling of pts treated with cabiralizumab (cabira) + nivolumab (NIVO) provide evidence of on-target tumor immune modulations and support future clinical applications.
Sign Up to like & getrecommendations! Published in 2018 at "Journal of Clinical Oncology"
DOI: 10.1200/jco.2018.36.15_suppl.3020
Abstract: 3020Background: Colony stimulating factor 1 receptor (CSF-1R) signaling supports recruitment, development, and maintenance of immune suppressive macrophages within the tumor. Combining anti–CSF-1R ... read more here.
Keywords: pts treated; pharmacodynamics genomic; profiling pts; genomic profiling ... See more keywords
Associations of incidence of common adverse events (AEs) and survival outcomes in metastatic colorectal cancer (mCRC) patients (pts) treated with first line chemotherapy: Findings from 9,812 pts in the ARCAD database.
Sign Up to like & getrecommendations! Published in 2018 at "Journal of Clinical Oncology"
DOI: 10.1200/jco.2018.36.4_suppl.617
Abstract: 617Background: There is limited, often conflicting evidence about AE timing, severity or associations with outcomes with the use of cytotoxic agents in cancer treatment. We investigated the impact on overall survival (OS) and progression-free survival… read more here.
Keywords: chemotherapy; line; first line; pts treated ... See more keywords
Efficacy of immune checkpoint inhibitors (ICI) and genomic characterization of sarcomatoid and/or rhabdoid (S/R) metastatic renal cell carcinoma (mRCC).
Sign Up to like & getrecommendations! Published in 2019 at "Journal of Clinical Oncology"
DOI: 10.1200/jco.2019.37.15_suppl.4514
Abstract: 4514 Background: S/R mRCC are poorly characterized rapidly progressing tumors associated with poor prognosis. Although conventional therapies are less effective for these tumors, emerging data suggests that ICIs may be especially effective. Our aim was… read more here.
Keywords: pts treated; non ici; mrcc; cell ... See more keywords
Impact of treatment sequence in metastatic castration-resistant prostate cancer (mCRPC) on outcome in a prospective cohort study.
Sign Up to like & getrecommendations! Published in 2019 at "Journal of Clinical Oncology"
DOI: 10.1200/jco.2019.37.7_suppl.264
Abstract: 264 Background: Abiraterone (Abi), enzalutamide (Enza) and docetaxel (Doc) are all valid first-line (1L) mCRPC treatment options. Evidence suggests a degree of cross-resistance between agents, which may impact the efficacy of subsequent lines of therapy.… read more here.
Keywords: abi; treatment; pts treated; doc ... See more keywords
Sites of metastases (mets) and their association with clinical outcomes (CO) in urothelial cancer patients (pts) treated with immunotherapy (IO).
Sign Up to like & getrecommendations! Published in 2019 at "Journal of Clinical Oncology"
DOI: 10.1200/jco.2019.37.7_suppl.473
Abstract: 473 Background: Several IO agents have been approved for treatment of advanced urothelial cancer pts. We investigated the association between sites of mets and CO in urothelial cancer pts treated with IO in the real… read more here.
Keywords: cancer pts; months month; pts treated; cancer ... See more keywords
Sites of metastasis (mets) and association with clinical outcomes (CO) in metastatic renal cell carcinoma (mRCC) patients (pts) treated with cabozantinib (cabo).
Sign Up to like & getrecommendations! Published in 2019 at "Journal of Clinical Oncology"
DOI: 10.1200/jco.2019.37.7_suppl.585
Abstract: 585 Background: Cabo is approved for the treatment for mRCC. We investigated the association of sites of mets and clinical outcomes (CO) in mRCC pts treated with cabo. Methods: We performed a retrospective analysis of… read more here.
Keywords: pts treated; mrcc; sites mets; mrcc pts ... See more keywords